ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Alpha Cognition Inc. Common Stock (ACOG) stock declined over -3.37%, trading at $5.44 on NASDAQ, down from the previous close of $5.63. The stock opened at $5.54, fluctuating between $5.43 and $5.79 in the recent session.
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
Employees | 5 |
Beta | 2.51 |
Sales or Revenue | N/A |
5Y Sales Change% | N/A |
Fiscal Year Ends | N/A |
Sector | Financial Services |
Industry | Financial - Conglomerates |